STAT Plus: Can Anne Wojcicki save 23andMe?
Matt’s Take
Matthew Herper is a senior medicine writer at STAT. He has covered medical innovation for decades, joining STAT in 2019 after 18 years at Forbes. In addition to writing news and columns, he also directs the editorial aspects of STAT’s events, including our highly regarded summits.
Latest
STAT Plus: How controversial was the decision by FDA’s Peter Marks to approve Sarepta’s gene therapy? Check its footnotes
New data show the HPV vaccine prevents cancer in men, too. Why don’t more people get it?
STAT Plus: Matt & Adam’s Take: Amylyx did the right thing by withdrawing its ALS drug. That’s rare and worthy of praise
A study says intermittent fasting is making people drop dead. Oh, come on
STAT Plus: Biden’s SOTU highlights pharma’s biggest political problem: It is terrifyingly, awfully alone
STAT Plus: Novo’s Catalent deal is great for GLP-1s. But what about drug manufacturing?
STAT Plus: Illumina says it will divest Grail, starting a closing chapter for a disastrous deal
All Coverage
advertisement
